Impact of Optimal Therapy and Prognostic Factors in Malignant Germ Cell Tumors of Ovary: 20 Years' Institutional Experience
- PMID: 36187515
- PMCID: PMC9515283
- DOI: 10.1007/s13193-022-01537-3
Impact of Optimal Therapy and Prognostic Factors in Malignant Germ Cell Tumors of Ovary: 20 Years' Institutional Experience
Abstract
The objective of this study is to analyze the impact of clinicopathological and treatment-related factors on survival in patients with malignant ovarian germ cell tumor. A total of 253 patients of ovarian germ cell malignancy were retrospectively reviewed during 2000-2019. Out of these, 111 had primary treatment at our institute, which is a dedicated regional cancer center. The remaining 142 were operated elsewhere and were referred to us for adjuvant chemotherapy or with recurrent disease. The clinicopathological and treatment-related characteristics were analyzed for association with tumor persistence/recurrence or death. Among them, 107 were dysgerminomas; 60 had endodermal sinus tumor, 53 mixed germ cell tumors, and 31 immature teratoma; and one each had embryoma and primitive germ cell tumor. The median follow-up period was 19 months (range 0-214). Median time to recurrence or progression was 5 months. Forty-nine patients (19.4%) had a recurrence and there were 16 (6.3%) deaths. Five-year disease-free-survival was 71.3% and 5-year overall survival rate was 88.1%, for the entire cohort. Disease-free-survival was 90.4% and overall survival was 92.1% for patients entirely treated at the reporting institute. Sub-group analysis based on treatment adequacy showed that survival rate was 91.0% in patients who had timely and complete initial treatment versus 78.3% in patients where treatment was incomplete or delayed (p = 0.032). Factors affecting relapse were tumor histology, absence of surgical staging, presence of residual disease, inadequate response to chemotherapy, treatment outside reporting institute, and incomplete/delayed chemotherapy. Significant factors adversely affecting survival were presence of post-operative residual disease, tumor histology, incomplete response to chemotherapy, and inadequate/delayed treatment at primary setting. There was no statistically significant difference based on disease stage and whether fertility-sparing surgery or non-fertility-sparing surgery was performed. Prognosis of ovarian germ cell malignancies is excellent with timely, optimal treatment. The outcome improves significantly if managed adequately in the primary setting, involving dedicated gynecologic oncologists.
Keywords: Clinicopathological and treatment-related factors; Fertility-sparing surgery; Malignant ovarian germ cell tumor.
© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022.
Conflict of interest statement
Conflict of InterestThe authors declare no competing interests.
Figures
Similar articles
-
Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution.World J Surg Oncol. 2011 Oct 11;9:123. doi: 10.1186/1477-7819-9-123. World J Surg Oncol. 2011. PMID: 21988930 Free PMC article. Clinical Trial.
-
Outcome and prognostic factors in ovarian germ cell malignancies.Gynecol Oncol. 2005 Mar;96(3):784-91. doi: 10.1016/j.ygyno.2004.11.027. Gynecol Oncol. 2005. PMID: 15721426
-
Germ Cell Tumor Ovary: an Institutional Experience of Treatment and Survival Outcomes.Indian J Surg Oncol. 2018 Jun;9(2):215-219. doi: 10.1007/s13193-018-0742-x. Epub 2018 Apr 10. Indian J Surg Oncol. 2018. PMID: 29887704 Free PMC article.
-
Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.Curr Treat Options Oncol. 2016 Aug;17(8):44. doi: 10.1007/s11864-016-0416-2. Curr Treat Options Oncol. 2016. PMID: 27357180 Review.
-
Current management of malignant germ cell tumor of the ovary.Gan To Kagaku Ryoho. 1995 Aug;22 Suppl 3:262-76. Gan To Kagaku Ryoho. 1995. PMID: 7661594 Review.
References
-
- Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer Oxf Engl 1990. 2011;47(17):2493–511. - PubMed
-
- Koonings PP, Campbell K, Mishell DR, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74(6):921–926. - PubMed
-
- Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018;29 Suppl 4:iv1–18 - PubMed
-
- Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol. 2000;95(1):128–133. - PubMed
LinkOut - more resources
Full Text Sources